Blog

What is a regulatory submission? Learn the types of FDA submissions, how dossiers are structured under the CTD & how submissions are filed & validated.

A regulatory submission is a formal package of documents, data, and evidence submitted to a competent health authority (such as the US Food and Drug Administration (FDA) or the European Medicines Agency (EMA)). Its objective is to demonstrate that a medicinal product meets the required standards of safety, efficacy, and quality.

For biopharmaceutical organizations, the regulatory submission process spans years of clinical development. Content requirements, format specifications, review timelines, and legal obligations depend on the submission type, the target regulatory market, and the stage of development. For most major markets, submissions must follow the Common Technical Document (CTD) structure and be delivered electronically in eCTD format.

What is the Purpose of a Regulatory Submission?

Regulatory submissions serve two purposes, namely authorizing clinical investigation and authorizing commercial marketing. These two submission categories differ across regulatory purpose, content focus, and submission requirements.

	Authorizing Clinical Investigation	Authorizing Commercial Marketing
Regulatory Purpose	Requesting permission from a health authority to administer an investigational drug to human study participants	Requesting approval to sell a drug to patients
Content Focus	Preclinical safety data, proposed clinical protocols, and manufacturing information sufficient to protect study participants	Complete accumulated clinical, nonclinical, and chemistry, manufacturing and controls (CMC) evidence organized to support a benefit-risk conclusion across the intended patient population
Submission Requirements	Must be structured and formatted to the receiving health authority's specifications	Must be structured and formatted to the receiving health authority's specifications

Both types must be designed and formatted to the receiving health authority's specifications. Submissions that fail to meet format or technical requirements are returned before scientific review begins, resetting the review timeline.

What are the Different Types of FDA Regulatory Submissions?

The primary types of FDA regulatory submissions across the drug development lifecycle include:

• Investigational New Drug Application (IND): Filed before human trials begin, requesting FDA authorization to administer an investigational compound to human study participants. Once submitted, the sponsor must wait 30 calendar days before initiating any clinical trials. If FDA does not issue a clinical hold during that period, the trial may proceed.

• New Drug Application (NDA): The channel through which drug sponsors formally request FDA approval to sell and market a new pharmaceutical in the US. The NDA presents the complete body of clinical, nonclinical, and CMC evidence accumulated during clinical development under the IND.

• Biologics License Application (BLA): The biologic equivalent of an NDA, required for vaccines, gene therapies, blood products, and other biological products regulated under the Public Health Service Act rather than the Federal Food, Drug, and Cosmetic Act.

• Abbreviated New Drug Application (ANDA): Filed for generic drug approval. ANDAs are abbreviated because they do not require independent preclinical or clinical trial data. Instead, they demonstrate bioequivalence to an FDA-approved reference listed drug.

• Marketing Authorization Application (MAA): Outside the US, the primary equivalent for EU-wide market authorization, submitted to the EMA under the centralized procedure. Like FDA marketing applications, the MAA follows the CTD structure and is accepted in eCTD format.

The documentation lifecycle connecting IND to NDA spans years of interconnected regulatory documents that must remain internally consistent, cross-referenced to source data, and eCTD-ready at submission.

How Regulatory Submissions are Structured

Most major regulatory authorities globally (including the FDA, EMA, PMDA in Japan, Health Canada, and more than 60 others) accept submissions organized under the CTD, a five-module content architecture standardized by the International Council for Harmonisation (ICH). Modules 2 through 5 are globally harmonized while Module 1 is region-specific and differs by authority.

The five CTD modules organize all submission content as follows:

• Module 1, Regional Information: Administrative and prescribing information specific to each submission market, including application forms, proposed labeling, cover letters, and region-specific requirements. Module 1 content is not standardized by ICH and differs between FDA, EMA, PMDA, and other authorities.

• Module 2, CTD Summaries: Quality, nonclinical, and clinical overviews and summaries that synthesize the scientific evidence in Modules 3, 4, and 5. Module 2 is typically written after the lower modules are complete; it is the integrated scientific argument that regulators read first.

• Module 3, Quality (CMC): Chemistry, manufacturing and controls documentation covering the drug substance, drug product formulation, and manufacturing processes.

• Module 4, Nonclinical Study Reports: Pharmacology, pharmacokinetics, and toxicology data from preclinical laboratory and animal studies.

• Module 5, Clinical Study Reports: All human clinical trial data from Phase I through Phase III, including individual study reports, integrated safety and efficacy summaries, and relevant clinical literature.

How Regulatory Submissions are Filed and Validated

Most major regulatory agencies require electronic submission via secure digital gateways, using the eCTD format with an XML backbone that structures content files, metadata, and lifecycle instructions.

Gateway and format requirements by major agencies include:

• FDA: Submissions delivered through the FDA Electronic Submissions Gateway (ESG). All commercial NDAs, BLAs, ANDAs, and INDs must be submitted in eCTD format. The ESG validates each submission's structure on receipt and routes accepted sequences to the appropriate review division.

• EMA: Submissions for centralized procedure applications are delivered via the EMA eSubmission Gateway or web client. All centralized procedure eCTD submissions automatically undergo full technical validation, and an automated success or failure acknowledgment is sent to the applicant.

Before scientific review begins, submissions undergo automated technical validation. The XML backbone, file structure, and dataset formatting are checked against the applicable eCTD specification for completeness and compliance. At FDA, this validation check determines whether the submission is accepted into FDA's systems or technically rejected at the gateway.

Technical validation failure is one of the most common and avoidable causes of submission delay. The documentation practices that produce audit-ready, technically valid submissions require consistent source traceability and version control across all modules from the earliest stages of authoring.

How AuroraPrime Accelerates Regulatory Submission Documentation

The content inside a regulatory dossier must be internally consistent, cross-referenced, and eCTD-formatted before technical validation and scientific review can begin. The documentation burden compounds across every phase of development, and manual authoring workflows were not engineered for the volume or precision that modern submissions require.

AuroraPrime, AlphaLife Sciences' AI for regulatory document authoring, automates the most resource-intensive tasks across the CTD:

• Module 5 Authoring: AI-driven CSR first-draft generation with up to 90% reduction in draft time, automated TFL data synchronization, and patient safety narrative automation.

• Module 2 Generation: Clinical overviews and integrated summaries auto-generated from Module 5 source documents, ensuring narrative consistency between study-level reports and the top-level regulatory summaries that reviewers read first.

• Cross-Module Quality Control: GenAI quality control benchmarked against validated regulatory documents, identifying inconsistencies between modules before submission and directly reducing the most common source of FDA review queries.

• Audit-Ready Traceability: Track and document every authoring decision across document versions and submission sequences, supporting eCTD lifecycle management and audit readiness.

As an AI for regulatory document authoring and a purpose-built AI writing solution, AuroraPrime addresses the workflow gaps that cause submission delays.

Book a demo with AlphaLife Sciences to see how AuroraPrime compresses regulatory submission documentation timelines across all five CTD modules.